INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™GlobeNewsWire • 03/05/24
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/12/24
INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024GlobeNewsWire • 02/06/24
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease ProgramGlobeNewsWire • 01/30/24
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate CancerGlobeNewsWire • 01/02/24
INmune Bio Provides Update Regarding Global Alzheimer's Phase II Clinical Trial and Clinical Hold Issued by the United States FDAGlobeNewsWire • 12/18/23
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer SymposiumGlobeNewsWire • 11/29/23
INmune Bio Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer's DiseaseGlobeNewsWire • 11/27/23
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in EuropeGlobeNewsWire • 11/15/23
INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business UpdateGlobeNewsWire • 11/01/23
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search AuthorityGlobeNewsWire • 10/31/23
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPαGlobeNewsWire • 10/30/23
Capitalizing On Inflammation's Role In Neurological Disease Part 2: INmune BioSeeking Alpha • 10/26/23
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewsWire • 10/17/23
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1GlobeNewsWire • 10/16/23
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer's DiseaseGlobeNewsWire • 09/05/23
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business UpdateGlobeNewsWire • 08/07/23
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7GlobeNewsWire • 07/31/23
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.GlobeNewsWire • 07/12/23